Clinical characteristics and prognosis of very late-onset myasthenia gravis in China

Alteration in onset-age distribution in myasthenia gravis (MG) and its increasing prevalence among the elderly underscores the need for a better understanding of the clinical course of MG and the establishment of personalized treatment. In this study we reviewed the demographics, clinical profile, and treatment of MG. Based on onset age, eligible patients were classified as early-onset MG (onset age >= 18 and < 50 years), late-onset MG (onset age >= 50 and < 65 years), and very late-onset MG (onset age >= 65 years). Overall, 1160 eligible patients were enrolled. Patients with late- and very late-onset MG showed a male predominance ( P = 0.02), ocular MG subtype ( P = 0.001), and seropositivity for acetylcholine receptors and titin antibodies ( P < 0.001). In very late-onset MG, a lower proportion of patients retained minimal manifestations status or better, a higher proportion of patients had MG-related deaths ( P < 0.001), and a shorter maintenance time of minimal manifestation status or better was seen at the last follow-up ( P = 0.007) than that in patients with early- and late-onset MG. Non-immunotherapy may associated with a poor prognosis in patients in the very late-onset group. Further studies on very late-onset MG patients should be performed to evaluate the relationship between immunotherapy and prognosis. (c) 2023 Elsevier B.V. All rights reserved.